<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0">
<channel>
<title>Meyers Primary Care Institute Publications and Presentations</title>
<copyright>Copyright (c) 2013 University of Massachusetts Medical School All rights reserved.</copyright>
<link>http://escholarship.umassmed.edu/meyers_pp</link>
<description>Recent documents in Meyers Primary Care Institute Publications and Presentations</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 May 2013 11:38:32 PDT</lastBuildDate>
<ttl>3600</ttl>








<item>
<title>Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/639</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/639</guid>
<pubDate>Thu, 31 Jan 2013 08:15:02 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Little is known about the extent of antiepileptic drug (AED) use in pregnancy, particularly for newer agents. Our objective was to assess whether AED use has increased among pregnant women in the US, 2001-2007.</p>
<p>METHODS:   We analysed data from the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) database, 1 January 2001 to 31 December 2007. We identified liveborn deliveries among women, aged 15-45 years on delivery date, who were members of MEPREP health plans (n=585615 deliveries). Pregnancy exposure to AEDs, determined through outpatient pharmacy dispensing files. Older AEDs were available for clinical use before 1993; other agents were considered newer AEDs. Information on sociodemographic and medical/reproductive factors was obtained from linked birth certificate files. Maternal diagnoses were identified based on ICD-9 codes.</p>
<p>RESULTS:   Prevalence of AED use during pregnancy increased between 2001 (15.7 per 1000 deliveries) and 2007 (21.9 per 1000 deliveries), driven primarily by a fivefold increase in the use of newer AEDs. Thirteen per cent of AED-exposed deliveries involved a combination of two or more AEDs. Psychiatric disorders were the most prevalent diagnoses, followed by epileptic and pain disorders, among AED users regardless of AED type, year of conception or gestational period.</p>
<p>CONCLUSIONS:   AED use during pregnancy increased between 2001 and 2007, driven by a fivefold increase in the use of newer AEDs. Nearly one in eight AED-exposed deliveries involved the concomitant use of more than one AED. Additional investigations of the reproductive safety of newer AEDs may be needed.</p>

	]]>
</description>

<author>William V. Bobo et al.</author>


<category>Epilepsy</category>

<category>Anticonvulsants</category>

<category>Pregnancy</category>

</item>






<item>
<title>Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007</title>
<link>http://escholarship.umassmed.edu/meyers_pp/638</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/638</guid>
<pubDate>Thu, 31 Jan 2013 08:14:58 PST</pubDate>
<description>
	<![CDATA[
	<p>OBJECTIVE: To describe the prevalence, trends, and patterns in use of antidiabetic medications to treat hyperglycemia and insulin resistance before and during pregnancy in a large U.S. cohort of insured pregnant women.</p>
<p>METHODS: Pregnancies resulting in live births were identified (N=437,950) from 2001 to 2007 among 372,543 females 12-50 years of age at delivery from 10 health maintenance organizations participating in the Medication Exposure in Pregnancy Risk Evaluation Program. Information for these descriptive analyses, including all antidiabetic medications dispensed during this period, was extracted from electronic health records and newborn birth certificates.</p>
<p>RESULTS: A little more than 1% (1.21%) of deliveries were to women dispensed antidiabetic medication in the 120 days before pregnancy. Use of antidiabetic medications before pregnancy increased from 0.66% of deliveries in 2001 to 1.66% of deliveries in 2007 (P<.001) because of an increase in metformin use. Most women using metformin before pregnancy had a diagnosis code for polycystic ovaries or female infertility (67.2%), whereas only 13.6% had a diagnosis code for diabetes. The use of antidiabetic medications during the second or third trimester of pregnancy increased from 2.8% of deliveries in 2001 to 3.6% in 2007 (P<.001). Approximately two thirds (68%) of women using metformin before pregnancy did not use any antidiabetic medications during pregnancy.</p>
<p>CONCLUSIONS: Antidiabetic medication use before and during pregnancy increased from 2001 to 2007, possibly because of increasing prevalence of gestational diabetes mellitus, type 1 and type 2 diabetes, and other conditions associated with insulin resistance.</p>
<p>LEVEL OF EVIDENCE: III.</p>

	]]>
</description>

<author>Jean M. Lawrence et al.</author>


<category>Diabetes Mellitus</category>

<category>Diabetes, Gestational</category>

<category>Pregnancy in Diabetics</category>

<category>Hypoglycemic Agents</category>

</item>






<item>
<title>Long-term safety of pegloticase in chronic gout refractory to conventional treatment</title>
<link>http://escholarship.umassmed.edu/meyers_pp/637</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/637</guid>
<pubDate>Fri, 04 Jan 2013 11:32:19 PST</pubDate>
<description>
	<![CDATA[
	<p>OBJECTIVE: To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout.</p>
<p>METHODS: This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing either of two replicate randomised placebo-controlled 6-month trials received pegloticase 8 mg every 2 weeks (biweekly) or every 4 weeks (monthly). Safety was evaluated as the primary outcome, with special interest in gout flares and infusion-related reactions (IRs). Secondary outcomes included urate-lowering and clinical efficacy.</p>
<p>RESULTS: Patients (n=149) received a mean+/-SD of 28+/-18 pegloticase infusions and were followed for a mean of 25+/-11 months. Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment. In 10 of the 11 patients with a serious IR, the event occurred when uric acid exceeded 6 mg/dl. Plasma and serum uric acid levels remained /dl in most randomised controlled trial (RCT)-defined pegloticase responders throughout the OLE study and were accompanied by sustained and progressive improvements in tophus resolution and flare incidence.</p>
<p>CONCLUSIONS: The safety profile of long-term pegloticase treatment was consistent with that observed during 6 months of RCT treatment; no new safety signals were identified. Improvements in clinical status, in the form of flare and tophus reduction initiated during RCT pegloticase treatment in patients maintaining goal range urate-lowering responses were sustained or advanced during up to 2.5 years of additional treatment.</p>

	]]>
</description>

<author>Michael A. Becker et al.</author>


<category>Gout</category>

<category>Polyethylene Glycols</category>

<category>Urate Oxidase</category>

</item>






<item>
<title>Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice</title>
<link>http://escholarship.umassmed.edu/meyers_pp/636</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/636</guid>
<pubDate>Fri, 04 Jan 2013 11:32:18 PST</pubDate>
<description>
	<![CDATA[
	<p>Background- Implantable cardioverter-defibrillators (ICDs) are increasingly used for primary prevention after randomized, controlled trials demonstrating that they reduce the risk of death in patients with left ventricular systolic dysfunction. The extent to which the clinical characteristics and long-term outcomes of unselected, community-based patients with left ventricular systolic dysfunction undergoing primary prevention ICD implantation in a real-world setting compare with those enrolled in the randomized, controlled trials is not well characterized. This study is being conducted to address these questions.</p>
<p>Methods and Results- The study cohort includes consecutive patients undergoing primary prevention ICD placement between January 1, 2006 and December 31, 2009 in 7 health plans. Baseline clinical characteristics were acquired from the National Cardiovascular Data Registry ICD Registry. Longitudinal data collection is underway, and will include hospitalization, mortality, and resource use from standardized health plan data archives. Data regarding ICD therapies will be obtained through chart abstraction and adjudicated by a panel of experts in device therapy. Compared with the populations of primary prevention ICD therapy randomized, controlled trials, the cohort (n=2621) is on average significantly older (by 2.5-6.5 years), more often female, more often from racial and ethnic minority groups, and has a higher burden of coexisting conditions. The cohort is similar, however, to a national population undergoing primary prevention ICD placement.</p>
<p>Conclusions- Patients undergoing primary prevention ICD implantation in this study differ from those enrolled in the randomized, controlled trials that established the efficacy of ICDs. Understanding a broad range of health outcomes, including ICD therapies, will provide patients, clinicians, and policy makers with contemporary data to inform decision-making.</p>

	]]>
</description>

<author>Frederick A. Masoudi et al.</author>


<category>Defibrillators, Implantable</category>

</item>






<item>
<title>The Johns Hopkins Hospital template for urologic cytology samples : Parts II and III-Improving the predictability of indeterminate results in urinary cytologic samples: an outcomes and cytomorphologic study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/635</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/635</guid>
<pubDate>Fri, 04 Jan 2013 11:32:17 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Urine cytology represents a major portion of testing volume in many cytopathology laboratories.</p>
<p>METHODS: The authors previously reported a template designed to standardize urothelial diagnostic categories to enable clinicians to uniformly manage their patients. In this study, they examined the common cytomorphologic features observed in specimens diagnosed with atypical urothelial cells, cannot exclude high-grade urothelial carcinoma (AUC-H), which prove most predictive of high-grade urothelial carcinoma (HGUC).</p>
<p>RESULTS: The most common morphologic features observed in the AUC-H specimens were hyperchromasia, irregular nuclear borders, increased nucleus-to-cytoplasm ratio, and anisonucleosis. Of the 58 patients who had specimens diagnosed with AUC-H, 95% ultimately were diagnosed with HGUC on follow-up biopsy over the study period. The small number of patients who had AUC-H with non-HGUC follow-up did not allow for a statistical comparison to determine the predictive ability of the selected criteria for HGUC. Next, the authors used the same features to examine a subset of urine samples that were diagnosed with atypical urothelial cells of unknown significance (AUC-US) in an attempt to improve the predictive value of this clinically frustrating category. A blind review was performed of 290 urine specimens from 217 patients. In contrast to the AUC-H specimen cohort, the majority of specimens with AUC-US did not contain atypical cells with the 4 common morphologic features. All 4 features significantly predicted HGUC in surveillance patients, but not in patients with hematuria.</p>
<p>CONCLUSIONS: Hyperchromasia was the strongest predictor of HGUC by far in patients who were undergoing surveillance (odds ratio, 9.81). Hyperchromasia remained statistically significant in multivariate analysis, indicating its predictive strength even in the absence of other features. Cancer (Cancer Cytopathol) 2012. (c) 2012 American Cancer Society.</p>

	]]>
</description>

<author>Christopher J. Vandenbussche et al.</author>


<category>Urinalysis</category>

<category>Cytological Techniques</category>

</item>






<item>
<title>The Johns Hopkins Hospital template for urologic cytology samples : Part I-Creating the template</title>
<link>http://escholarship.umassmed.edu/meyers_pp/633</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/633</guid>
<pubDate>Fri, 04 Jan 2013 11:32:16 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: The most important indicator for urologic surgeons at The Johns Hopkins Hospital to have a patient undergo cystoscopy is a cytologic diagnosis of high-grade urothelial carcinoma. The template was designed to standardize diagnostic categories so clinicians can manage their patients uniformly. The template was based in part on the Bethesda System for cervical cytology.</p>
<p>METHODS: According to the template, reactive/inflammatory changes were included in the negative group (no urothelial atypia or malignancy identified). The category atypical urothelial cells of undetermined significance (AUC-US) was akin to atypical squamous cells of undetermined significance (ASC-US), as was the category of atypical urothelial cells, favor high-grade carcinoma (AUC-H). The categories high-grade urothelial carcinoma (HGUC) and low-grade urothelial carcinoma also were added.</p>
<p>RESULTS: The Pathology Data System at the Johns Hopkins Hospital was searched for cases that met the following criteria over a period from July 1, 2007 to June 30, 2009: all cytologic specimens from the urinary tract and all surgical specimens with a diagnosis of HGUC, regardless of invasion status. All cytologic specimens were then matched with biopsies during the same period, and all surgical specimens from patients who had a cytologic diagnosis of AUC-US or AUC-H were retrieved for 18 months after the end of the 2-year study period. Greater than 50% of patients who had biopsy-confirmed HGUC had a preceding cytologic diagnosis of AUC-H or HGUC. When patients with AUC-US were added to the analysis, 80% of patients with HGUC had at least 1 abnormal urinary cytology result. Of those patients who had a diagnosis of AUC-H, 38% had urothelial cancer discovered at biopsy compared with only 10% of those with an AUC-US diagnosis.</p>
<p>CONCLUSIONS: The authors concluded that their template is effective in targeting those patients who need to undergo cystoscopy.</p>

	]]>
</description>

<author>Dorothy L. Rosenthal et al.</author>


<category>Urinalysis</category>

<category>Cytological Techniques</category>

</item>






<item>
<title>A review of reporting systems and terminology for urine cytology</title>
<link>http://escholarship.umassmed.edu/meyers_pp/634</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/634</guid>
<pubDate>Fri, 04 Jan 2013 11:32:16 PST</pubDate>
<description>
	<![CDATA[
	<p>Urine cytology continues to play an important role in the diagnosis and management of urothelial carcinoma, a common cancer of adults with significant morbidity and mortality. Because of its high sensitivity for high-grade urothelial tumors, including lesions that may be cystoscopically occult, urine cytology nicely compliments cystoscopic examination, a method that detects most low-grade tumors. Over the decades, several reporting schemes for urine cytology have been published in the literature, each of which has relative strengths and weaknesses. Unlike cervical cytology, there has not been widespread acceptance and use of any particular reporting scheme for urine cytology studies. Thus, terminology and criteria for urine cytology reporting are not uniform among pathologists, which can frustrate clinicians and hinders interlaboratory comparisons. Cancer (Cancer Cytopathol) 2012. (c) 2012 American Cancer Society.</p>

	]]>
</description>

<author>Christopher L. Owens et al.</author>


<category>Urinalysis</category>

<category>Cytological Techniques</category>

</item>






<item>
<title>Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/632</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/632</guid>
<pubDate>Fri, 04 Jan 2013 11:32:15 PST</pubDate>
<description>
	<![CDATA[
	<p>Obesity is associated with pathological cardiac remodeling and risk of heart failure (HF). Adipocytokines (ADKs) may mediate the increased risk of cardiovascular disease associated with excess adiposity. Yet data relating ADKs to cardiac remodeling phenotypes are sparse. We related two circulating ADKs, resistin and adiponectin, to three important echocardiographic markers of cardiac remodeling, left ventricular mass (LVM), left atrial diameter (LAD), and LV fractional shortening (LVFS) in 2,615 participants (mean age 61 years, 55% women) in the Framingham Offspring Study. Adiponectin concentrations were inversely related to LVM in multivariable linear regression models adjusting for key clinical correlates including BMI (regression coefficient per s.d.-increment in ln-adiponectin = -3.37, P = 0.02; P for trend across quartiles = 0.02). Adiponectin was not associated with LAD or LVFS (P > 0.56). Resistin concentrations were inversely related to LVFS (regression coefficient per s.d.-increment in ln-resistin = -0.01, P = 0.03; P for trend across quartiles = 0.04). Resistin was not associated with LVM or LAD (P > 0.05). In our moderate-sized, community-based sample, higher circulating concentrations of adiponectin and resistin were associated with lower LVM and lower LVFS, respectively. In conclusion, these associations identify potential mechanisms by which excess adiposity may mediate adverse cardiac remodeling and HF risk.</p>

	]]>
</description>

<author>David D. McManus et al.</author>


<category>Adiponectin</category>

<category>Atrial Function, Left</category>

<category>Obesity</category>

<category>Resistin</category>

<category>Ventricular Function, Left</category>

<category>Ventricular Remodeling</category>

</item>






<item>
<title>Automatic motion and noise artifact detection in Holter ECG data using empirical mode decomposition and statistical approaches</title>
<link>http://escholarship.umassmed.edu/meyers_pp/631</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/631</guid>
<pubDate>Fri, 04 Jan 2013 11:32:14 PST</pubDate>
<description>
	<![CDATA[
	<p>We present a real-time method for the detection of motion and noise (MN) artifacts, which frequently interferes with accurate rhythm assessment when ECG signals are collected from Holter monitors. Our MN artifact detection approach involves two stages. The first stage involves the use of the first-order intrinsic mode function (F-IMF) from the empirical mode decomposition to isolate the artifacts' dynamics as they are largely concentrated in the higher frequencies. The second stage of our approach uses three statistical measures on the F-IMF time series to look for characteristics of randomness and variability, which are hallmark signatures of MN artifacts: the Shannon entropy, mean, and variance. We then use the receiver-operator characteristics curve on Holter data from 15 healthy subjects to derive threshold values associated with these statistical measures to separate between the clean and MN artifacts' data segments. With threshold values derived from 15 training data sets, we tested our algorithms on 30 additional healthy subjects. Our results show that our algorithms are able to detect the presence of MN artifacts with sensitivity and specificity of 96.63% and 94.73%, respectively. In addition, when we applied our previously developed algorithm for atrial fibrillation (AF) detection on those segments that have been labeled to be free from MN artifacts, the specificity increased from 73.66% to 85.04% without loss of sensitivity (74.48%-74.62%) on six subjects diagnosed with AF. Finally, the computation time was less than 0.2 s using a MATLAB code, indicating that real-time application of the algorithms is possible for Holter monitoring.</p>

	]]>
</description>

<author>Jinseok Lee et al.</author>


<category>*Algorithms</category>

<category>*Artifacts</category>

<category>Atrial Fibrillation</category>

<category>Computer Systems</category>

<category>Diagnosis, Computer-Assisted</category>

<category>Electrocardiography, Ambulatory</category>

<category>Humans</category>

<category>Motion</category>

<category>Pattern Recognition, Automated</category>

<category>Reproducibility of Results</category>

<category>Sensitivity and Specificity</category>

<category>Signal-To-Noise Ratio</category>

</item>






<item>
<title>Management strategies in atrial fibrillation in patients with heart failure</title>
<link>http://escholarship.umassmed.edu/meyers_pp/630</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/630</guid>
<pubDate>Fri, 04 Jan 2013 11:32:13 PST</pubDate>
<description>
	<![CDATA[
	<p>Atrial fibrillation (AF) and heart failure (HF) frequently occur together, and their coexistence is associated with a poor prognosis. AF and HF share risk factors, but their relationship involves complex hemodynamic, neurohormonal, inflammatory, ultrastructural, and electrophysiologic processes that extend beyond epidemiological associations. The shared mechanisms underlying AF and HF have important implications for the treatment of AF in patients with HF. This article focuses on reviewing contemporary data as it pertains to AF management in patients with HF and provides insight into investigational therapies currently under development.</p>

	]]>
</description>

<author>Amir Y. Shaikh et al.</author>


<category>Atrial Fibrillation</category>

<category>Heart Failure</category>

</item>






<item>
<title>Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/629</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/629</guid>
<pubDate>Fri, 04 Jan 2013 11:32:12 PST</pubDate>
<description>
	<![CDATA[
	<p>CONTEXT: Fetuin-A, retinol-binding protein 4 (RBP4), and fatty-acid binding protein 4 (FABP4) are novel biomarkers that may link adiposity to insulin resistance and the metabolic syndrome (MetSyn).</p>
<p>OBJECTIVE: The aim of this study was to investigate the correlates of these three adiposity biomarkers in a large community-based sample.</p>
<p>DESIGN, SETTING, PARTICIPANTS, AND OUTCOMES: Serum concentrations of fetuin-A, RBP4, and FABP4 were assayed in 3658 participants of the Third Generation Framingham Heart Study cohort (mean age 40 yr, 54% women). We used multivariable regression to cross-sectionally relate biomarkers to insulin resistance, cardiovascular risk factors, and the MetSyn. The genetic contribution to inter-individual variation in biomarker levels was assessed using variance-components analysis.</p>
<p>RESULTS: All three biomarkers exhibited sexual dimorphisms (levels higher in women for fetuin-A and FABP4 but greater in men for RBP4) and were associated positively with insulin resistance assessed using the homeostasis model, with high-sensitivity C-reactive protein, and with prevalent MetSyn (P<0.01 for all). The biomarkers showed distinct patterns of association with metabolic risk factors. RBP4 levels were correlated with body mass index only in unadjusted but not in adjusted models. None of the biomarkers were associated with prevalent diabetes in multivariable models. Circulating fetuin-A, RBP4, and FABP4 levels showed modest heritability, ranging from 15-44% (all P<0.0001).</p>
<p>CONCLUSIONS: In our large young- to middle-aged community-based sample, we observed that circulating levels of fetuin-A, RBP4, and FABP4 are associated with insulin resistance and with distinct components of MetSyn consistent with the multifactorial pathogenesis of metabolic dysregulation.</p>

	]]>
</description>

<author>Bernhard M. Kaess et al.</author>


<category>Adiposity</category>

<category>Adult</category>

<category>Biological Markers</category>

<category>Body Mass Index</category>

<category>C-Reactive Protein</category>

<category>Cardiovascular Diseases</category>

<category>Fatty Acid-Binding Proteins</category>

<category>Female</category>

<category>Humans</category>

<category>Insulin Resistance</category>

<category>Male</category>

<category>Massachusetts</category>

<category>Metabolic Syndrome X</category>

<category>Middle Aged</category>

<category>Multivariate Analysis</category>

<category>Retinol-Binding Proteins, Plasma</category>

<category>Risk Factors</category>

<category>Sex Characteristics</category>

<category>Sex Distribution</category>

<category>alpha-2-HS-Glycoprotein</category>

</item>






<item>
<title>Increase in the proportion of patients hospitalized with acute myocardial infarction with do-not-resuscitate orders already in place between 2001 and 2007: a nonconcurrent prospective study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/626</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/626</guid>
<pubDate>Fri, 04 Jan 2013 11:32:09 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND AND OBJECTIVE: Shared decision making and advance planning in end-of-life decisions have become increasingly important aspects of the management of seriously ill patients. Here, we describe the use and timing of do-not-resuscitate (DNR) orders in patients hospitalized with acute myocardial infarction (AMI).</p>
<p>STUDY DESIGN AND SETTING: The nonconcurrent prospective study population consisted of 4182 patients hospitalized with AMI in central Massachusetts in four annual periods between 2001 and 2007.</p>
<p>RESULTS: One-quarter (25%) of patients had a DNR order written either prior to or during hospitalization. The frequency of DNR orders remained constant (24% in 2001; 26% in 2007). Among patients with DNR orders, there was a significant increase in orders written prior to hospitalization (2001: 9%; 2007: 55%). Older patients and those with a medical history of heart failure or myocardial infarction were more likely to have prior DNR orders than respective comparison groups. Patients with prior DNR orders were less likely to die 1 month after hospitalization than patients whose DNRs were written during hospitalization.</p>
<p>CONCLUSION: Although the use of DNR orders in patients hospitalized with AMI was stable during the period under study, in more recent years, patients are increasingly being hospitalized with DNR orders already in place.</p>

	]]>
</description>

<author>Jane S. Saczynski et al.</author>


<category>Myocardial Infarction</category>

<category>Resuscitation Orders</category>

</item>






<item>
<title>A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation</title>
<link>http://escholarship.umassmed.edu/meyers_pp/624</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/624</guid>
<pubDate>Fri, 04 Jan 2013 11:32:08 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Atrial fibrillation (AF) is common and associated with adverse health outcomes. Timely detection of AF can be challenging using traditional diagnostic tools. Smartphone use is increasing and may provide an inexpensive and user-friendly means to diagnose AF.</p>
<p>OBJECTIVE: To test the hypothesis that a smartphone-based application could detect an irregular pulse from AF.</p>
<p>METHODS: Seventy-six adults with persistent AF were consented for participation in our study. We obtained pulsatile time series recordings before and after cardioversion using an iPhone 4S camera. A novel smartphone application conducted real-time pulse analysis using 2 statistical methods: root mean square of successive RR difference (RMSSD/mean) and Shannon entropy (ShE). We examined the sensitivity, specificity, and predictive accuracy of both algorithms using the 12-lead electrocardiogram as the gold standard.</p>
<p>RESULTS: RMSDD/mean and ShE were higher in participants in AF than in those with sinus rhythm. The 2 methods were inversely related to AF in regression models adjusting for key factors including heart rate and blood pressure (beta coefficients per SD increment in RMSDD/mean and ShE were-0.20 and-0.35; P</p>
<p>CONCLUSIONS: In a prospectively recruited cohort of 76 participants undergoing cardioversion for AF, we found that a novel algorithm analyzing signals recorded using an iPhone 4S accurately distinguished pulse recordings during AF from sinus rhythm. Data are needed to explore the performance and acceptability of smartphone-based applications for AF detection.</p>

	]]>
</description>

<author>David D. McManus et al.</author>


<category>Atrial Fibrillation</category>

<category>Diagnosis, Computer-Assisted</category>

<category>Algorithms</category>

<category>Heart Rate</category>

<category>Cellular Phone</category>

</item>






<item>
<title>Speckle echocardiographic left atrial strain and stiffness index as predictors of maintenance of sinus rhythm after cardioversion for atrial fibrillation: a prospective study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/625</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/625</guid>
<pubDate>Fri, 04 Jan 2013 11:32:08 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Echocardiographic left atrial (LA) strain parameters have been associated with atrial fibrillation (AF) in prior studies. Our goal was to determine if strain measures [peak systolic longitudinal strain (LAS) and stiffness index (LASt)] changed after cardioversion (CV); and their relation to AF recurrence.</p>
<p>METHODS AND RESULTS: 46 participants with persistent AF and 41 age-matched participants with no AF were recruited. LAS and LASt were measured before and immediately after CV using 2D speckle tracking imaging (2DSI). Maintenance of sinus rhythm was assessed over a 6-month follow up. Mean LAS was lower, and mean LASt higher, in participants with AF before CV as compared to control group (11.9 +/- 1.0 vs 35.7 +/- 1.7, p</p>
<p>CONCLUSIONS: LAS and LASt differed between participants with and without AF, irrespective of the rhythm at the time of echocardiographic assessment. Baseline LAS and LASt were not associated with AF recurrence. However, change in LAS after CV may be a useful predictor of recurrent arrhythmia.</p>

	]]>
</description>

<author>Amir Y. Shaikh et al.</author>


<category>Atrial Fibrillation</category>

<category>Electric Countershock</category>

</item>






<item>
<title>The Cancer Message Literacy Tests: psychometric analyses and validity studies</title>
<link>http://escholarship.umassmed.edu/meyers_pp/623</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/623</guid>
<pubDate>Fri, 04 Jan 2013 11:32:07 PST</pubDate>
<description>
	<![CDATA[
	<p>OBJECTIVE: To examine the psychometric properties of two new health literacy tests, and to evaluate score validity. METHODS: Adults aged 40-71 completed the Cancer Message Literacy Test-Listening (CMLT-Listening), the Cancer Message Literacy Test-Reading (CMLT-Reading), the REALM, the Lipkus numeracy test, a brief knowledge test (developed for this study) and five brief cognitive tests. Participants also self-reported educational achievement, current health, reading ability, ability to understand spoken information, and language spoken at home.</p>
<p>RESULTS: Score reliabilities were good (CMLT-Listening: alpha=.84) to adequate (CMLT-Reading: alpha=.75). Scores on both CMLT tests were positively and significantly correlated with scores on the REALM, numeracy, cancer knowledge and the cognitive tests. Mean CMLT scores varied as predicted according to educational level, language spoken at home, self-rated health, self-reported reading, and self-rated ability to comprehend spoken information.</p>
<p>CONCLUSION: The psychometric findings for both tests are promising. Scores appear to be valid indicators of comprehension of spoken and written health messages about cancer prevention and screening.</p>
<p>PRACTICE IMPLICATIONS: The CMLT-Listening will facilitate research into comprehension of spoken health messages, and together with the CMLT-Reading will allow researchers to examine the unique contributions of listening and reading comprehension to health-related decisions and behaviors.</p>

	]]>
</description>

<author>Kathleen M. Mazor et al.</author>


<category>Comprehension</category>

<category>Health Literacy</category>

<category>Neoplasms</category>

<category>Psychometrics</category>

<category>Questionnaires</category>

<category>Reading</category>

</item>






<item>
<title>Patients&apos; knowledge and beliefs concerning gout and its treatment: a population based study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/622</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/622</guid>
<pubDate>Fri, 04 Jan 2013 11:32:06 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: For patients to effectively manage gout, they need to be aware of the impact of diet, alcohol use, and medications on their condition. We sought to examine patients' knowledge and beliefs concerning gout and its treatment in order to identify barriers to optimal patient self-management.</p>
<p>METHODS: We identified patients (>/=18 years of age) cared for in the setting of a multispecialty group practice with documentation of at least one health care encounter associated with a gout diagnosis during the period 2008-2009 (n = 1346). Patients were sent a questionnaire assessing knowledge with regard to gout, beliefs about prescription medications used to treat gout, and trust in the physician. Administrative electronic health records were used to identify prescription drug use and health care utilization.</p>
<p>RESULTS: Two hundred and forty patients returned surveys out of the 500 contacted for participation. Most were male (80%), white (94%), and aged 65 and older (66%). Only 14 (6%) patients were treated by a rheumatologist. Only a minority of patients were aware of common foods known to trigger gout (e.g., seafood [23%], beef [22%], pork [7%], and beer [43%]). Of those receiving a urate-lowering medication, only 12% were aware of the short-term risks of worsening gout with initiation. These deficits were more common in those with active as compared to inactive gout.</p>
<p>CONCLUSION: Knowledge deficits about dietary triggers and chronic medications were common, but worse in those with active gout. More attention is needed on patient education on gout and self-management training.</p>

	]]>
</description>

<author>Leslie R. Harrold et al.</author>


<category>Gout</category>

<category>Patient Education</category>

</item>






<item>
<title>Dementia and risk of adverse warfarin-related events in the nursing home setting</title>
<link>http://escholarship.umassmed.edu/meyers_pp/621</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/621</guid>
<pubDate>Fri, 04 Jan 2013 11:32:05 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Little attention has been focused on the safety of medications administered to treat non illnesses in nursing home residents with dementia. It is unclear whether this population is at increased risk of adverse drug events.</p>
<p>OBJECTIVES: To test the hypotheses that in nursing home residents with dementia prescribed warfarin have less time in therapeutic range and a higher incidence of nonpreventable and preventable adverse warfarin events compared to nursing home residents without dementia after controlling for facility and patient characteristics.</p>
<p>METHODS: A prospective cohort embedded in a clinical trial of nursing home residents prescribed warfarin in 26 nursing homes in Connecticut was observed for up to 12 months. The primary outcome measures included adverse warfarin events (AWEs) (injuries resulting from warfarin use), potential AWEs (INR [international normalized ratio] >4.5 and management error), and AWE preventability based on physician reviews of medical record abstractions. Potential confounders included nursing home structural characteristics (eg, number of beds and for-profit status), nursing staff time, and nursing home regulatory deficiencies (pharmacy, administrative, quality of care, and all other deficiencies). Multivariable Poisson regression analysis was used to determine the independent association of dementia with potential and preventable AWEs using generalized estimating equations to account for clustering within nursing homes.</p>
<p>RESULTS: Residents with dementia had no difference in the number of INR monitoring tests or percentage of days in the therapeutic range, but did have an increased risk of AWEs (adjusted incidence rate ratio [IRR], 1.47; 95% confidence interval [CI], 1.20-1.82), and preventable or potential AWEs (adjusted IRR, 1.36; 95% CI, 1.06-1.76) after adjustment for patient characteristics, nursing home quality, and case mix. Greater nursing staff time was protective for preventable and potential AWEs (adjusted IRR, 0.66; 95% CI, 0.48-0.90) but not for nonpreventable AWEs.</p>
<p>CONCLUSION: A diagnosis of dementia was associated with increased risk of nonpreventable and preventable or potential AWEs. Greater nursing staff time was associated with lower risk of preventable AWEs. These findings have implications for quality-of-care reporting and patient safety.</p>

	]]>
</description>

<author>Jennifer Tjia et al.</author>


<category>Dementia</category>

<category>Warfarin</category>

<category>Nursing Homes</category>

<category>Drug Toxicity</category>

</item>






<item>
<title>Can Attention Control Conditions Have Detrimental Effects on Behavioral Medicine Randomized Trials</title>
<link>http://escholarship.umassmed.edu/meyers_pp/620</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/620</guid>
<pubDate>Fri, 04 Jan 2013 11:32:04 PST</pubDate>
<description>
	<![CDATA[
	<p>Objective: Attention control (AC) conditions are used to balance nonspecific attention in randomized trials of behavioral interventions. Very little guidance about which behavioral interventions and outcomes merit AC is available in the literature. The primary aim of the present study is to demonstrate a scenario in which use of AC in a behavioral randomized trial was unnecessary and possibly detrimental.</p>
<p>Methods: Exploratory analyses were performed in a randomized controlled trial that tested whether a patient-centered counseling intervention reduced low-density lipoprotein cholesterol levels in 355 participants with peripheral arterial disease, compared with AC and usual care (UC) conditions. The patient-centered counseling intervention was designed to activate participants to ask their physician for lipid-lowering medication and/or increase dose intensity, increase medication adherence, and reduce fat intake. The AC condition involved attention-matched telephone-delivered health education, and the UC condition consisted of an educational pamphlet.</p>
<p>Results: At 12-month follow-up, the mean low-density lipoprotein cholesterol changes were -11.1 and -6.8 mg/dL in the UC and AC conditions, respectively (p = .17). The proportion of participants who increased the use or dose intensity of medication was significantly lower in AC than in UC: 17.5% versus 30.5% (p = .03). No significant difference in other outcomes was observed between AC and UC.</p>
<p>Conclusions: AC has significantly worse medication outcomes, and there is no indication of a therapeutic effect on other end points. Implications for the use of AC in behavioral randomized trials are discussed.</p>
<p>Trial Registration:clinicaltrials.gov Identifier: NCT00217919.</p>

	]]>
</description>

<author>Sherry L. Pagoto et al.</author>


<category>Randomized Controlled Trials as Topic</category>

<category>Behavioral Medicine</category>

</item>






<item>
<title>Patient Completion of Laboratory Tests to Monitor Medication Therapy: A Mixed-Methods Study</title>
<link>http://escholarship.umassmed.edu/meyers_pp/619</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/619</guid>
<pubDate>Fri, 04 Jan 2013 11:32:03 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Little is known about the contribution of patient behavior to incomplete laboratory monitoring, and the reasons for patient non-completion of ordered laboratory tests remain unclear.</p>
<p>OBJECTIVE: To describe factors, including patient-reported reasons, associated with non-completion of ordered laboratory tests.</p>
<p>DESIGN: Mixed-Methods study including a quantitative assessment of the frequency of patient completion of ordered monitoring tests combined with qualitative, semi-structured, patient interviews.</p>
<p>PARTICIPANTS: Quantitative assessment included patients 18 years or older from a large multispecialty group practice, who were prescribed a medication requiring monitoring. Qualitative interviews included a subset of show and no-show patients prescribed a cardiovascular, anticonvulsant, or thyroid replacement medication.</p>
<p>MAIN MEASURES: Proportion of recommended monitoring tests for each medication not completed, factors associated with patient non-completion, and patient-reported reasons for non-completion.</p>
<p>KEY RESULTS: Of 27,802 patients who were prescribed one of 34 medications, patient non-completion of ordered tests varied (range: 0-24 %, by drug-test pair). Factors associated with higher odds of test non-completion included: younger patient age (< 40 years vs. >/= 80 years, adjusted odds ratio [AOR] 1.52, 95 % confidence interval [95 % CI] 1.27-1.83); lower medication burden (one medication vs. more than one drug, AOR for non-completion 1.26, 95 % CI 1.15-1.37), and lower visit frequency (0-5 visits/year vs. >/= 19 visits/year, AOR 1.41, 95 % CI 1.25 to 1.59). Drug-test pairs with black box warning status were associated with greater odds of non-completion, compared to drugs without a black box warning or other guideline for testing (AOR 1.91, 95 % CI 1.66-2.19). Qualitative interviews, with 16 no-show and seven show patients, identified forgetting as the main cause of non-completion of ordered tests.</p>
<p>CONCLUSIONS: Patient non-completion contributed to missed opportunities to monitor medications, and was associated with younger patient age, lower medication burden and black box warning status. Interventions to improve laboratory monitoring should target patients as well as physicians.</p>

	]]>
</description>

<author>Shira H. Fischer et al.</author>


<category>Medication Therapy Management</category>

<category>Patient Compliance</category>

<category>Diagnostic Tests, Routine</category>

</item>






<item>
<title>Community health worker encounter forms: a tool to guide and document patient visits and worker performance</title>
<link>http://escholarship.umassmed.edu/meyers_pp/618</link>
<guid isPermaLink="true">http://escholarship.umassmed.edu/meyers_pp/618</guid>
<pubDate>Fri, 04 Jan 2013 11:32:02 PST</pubDate>
<description>
	<![CDATA[
	<p>OBJECTIVES: We explored the benefits of using community health worker (CHW) encounter forms to collect data on patient interactions and assessed the effectiveness of these forms in guiding and directing interactions.</p>
<p>METHODS: A 1-page standardized encounter form was developed to document topics discussed during visits with diabetes patients. A portion of the form was designed to be used as a script to guide the interaction and assist patients in setting appropriate self-management goals. Data were also collected via CHW work logs and interviews with CHWs and their supervisors to validate findings.</p>
<p>RESULTS: Data were collected for 1198 interactions with 540 patients at 6 community health centers. Self-management goals were set during 62% of encounters. With respect to the most recent self-management goal set, patients who had set a challenging goal were more likely to be in the action stage of change than in other stages. Work logs revealed that CHWs engaged in a number of activities not involving direct patient interactions and thus not captured on encounter forms.</p>
<p>CONCLUSIONS: Evaluating and monitoring CHWs' daily activities has been challenging. Encounter forms have great potential for documenting the work of CHWs with patients.</p>

	]]>
</description>

<author>Celeste A. Lemay et al.</author>


<category>Community Health Centers</category>

<category>Community Health Workers</category>

<category>Humans</category>

<category>Massachusetts</category>

<category>Professional-Patient Relations</category>

<category>*Records as Topic</category>

<category>Self Care</category>

</item>





</channel>
</rss>
